BTLA marks a less cytotoxic T-cell subset in diffuse large B-cell lymphoma with high expression of checkpoints

The immune system plays an important role in the development of cancer [1,2], including hematologic malignancies [3]. PD-1 is highly expressed in the microenvironment of hematologic malignancies, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and classic Hodgkin lymphoma (cHL) [4 –6]. Cancer immunotherapy via immune checkpoint blockade, especially PD-1 blockade, has shown encouraging results in many clinical trials in DLBCL and cHL [7,8]. Recently, combinations of PD-1 blockade with other checkpoint inhibitors, such as CTLA-4, BTLA, TIM-3, LIGHT, and LAG-3, have emerged as a novel direction for lymphoma immunotherapy.

Source: Experimental Hematology - January 15, 2018 Category: Hematology Authors: Lina Quan, Xiuwen Lan, Yuanyuan Meng, Xiuchen Guo, Yiwei Guo, Lina Zhao, Xue Chen, Aichun Liu Source Type: research